Clinical outcomes in metabolic syndrome

被引:7
作者
Bhatheja, Rohit [1 ]
Bhatt, Deepak L.
机构
[1] Cleveland Clin Fdn, Dept Cardiovasc Med, Desk F25,9500 Euclid Ave, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Internal Med, Cleveland, OH 44195 USA
关键词
coronary artery disease; diabetes; metabolic syndrome; obesity;
D O I
10.1097/00005082-200607000-00011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metabolic syndrome is a clustering of cardiovascular risk factors. Its definition is the presence of any 3 of the following: obesity, hypertriglyceridemia, low high-density lipoprotein, hypertension, and impaired fasting glucose. The development of coronary artery disease is the most dreaded complication of this disease. In the United States, Mexican Americans and African American women are the most affected. Management of this syndrome includes physical exercise, weight loss, and effective drug treatment of dyslipidemia, high blood pressure, and impaired fasting blood glucose. Because of the increasing prevalence of obesity and diabetes, there is a rise in fatal and nonfatal cardiovascular events. With the development of effective antiplatelet medication and newer drug-eluting stents, percutaneous coronary intervention has become an effective revascularization strategy for those with coronary artery disease. Rates of stent restenosis and target-lesion revascularization have been reduced. Oral hypoglycemic drugs like thiazolidinediones improve insulin resistance and may have a favorable effect in those with metabolic syndrome. Diagnosis and appropriate management of metabolic syndrome are challenges as the presence of risk factors predates the coronary event.
引用
收藏
页码:298 / 305
页数:8
相关论文
共 55 条
[1]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]  
2-S
[3]  
Alderman EL, 1996, NEW ENGL J MED, V335, P217
[4]  
Alderman EL, 2000, J AM COLL CARDIOL, V35, P1122
[5]   Impact of insulin-requiring diabetes mellitus on effectiveness of reperfusion and outcome of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction [J].
Antoniucci, D ;
Valenti, R ;
Migliorini, A ;
Parodi, G ;
Moschi, G ;
Memisha, G ;
Santoro, GM ;
Cerisano, G .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (09) :1170-1172
[6]   DIABETES IN IDENTICAL-TWINS - A STUDY OF 200 PAIRS [J].
BARNETT, AH ;
EFF, C ;
LESLIE, RDG ;
PYKE, DA .
DIABETOLOGIA, 1981, 20 (02) :87-93
[7]   Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty [J].
Barsness, GW ;
Peterson, ED ;
Ohman, EM ;
Nelson, CL ;
DeLong, ER ;
Reves, JG ;
Smith, PK ;
Anderson, RD ;
Jones, RH ;
Mark, DB ;
Califf, RM .
CIRCULATION, 1997, 96 (08) :2551-2556
[8]   Abciximab reduces mortality in diabetics following percutaneous coronary intervention [J].
Bhatt, DL ;
Marso, SP ;
Lincoff, AM ;
Wolski, KE ;
Ellis, SG ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (04) :922-928
[9]   Amplified benefit of Clopidogrel versus aspirin in patients with diabetes mellitus [J].
Bhatt, DL ;
Marso, SP ;
Hirsch, AT ;
Ringleb, PA ;
Hacke, W ;
Topol, EJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (06) :625-+
[10]  
Borch-Johnsen K, 1999, LANCET, V354, P617